Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Pfizer Inc. (PFE) had Cost of Goods Sold of $16.07B for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$62.58B |
|
$7.77B |
|
|
Cost of Goods Sold |
$16.07B |
$46.51B |
|
$48.34B |
|
$14.24B |
|
$-6.72B |
|
$7.52B |
|
$7.52B |
|
$7.79B |
|
$7.79B |
|
$7.81B |
|
$7.79B |
|
$14.24B |
|
$14.24B |
|
5.68B |
|
5.71B |
|
$1.37 |
|
$1.36 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|